Article info

PDF
Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma

Authors

  • Maria del Carmen Vennera Department of Pneumology and Respiratory Allergy, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Barcelona, Spain PubMed articlesGoogle scholar articles
  • Carlos Sabadell Department of Pneumology, Hospital de Figueres, Figueres, Catalunya, Spain PubMed articlesGoogle scholar articles
  • Cesar Picado Department of Pneumology and Respiratory Allergy, Hospital Clinic, IDIBAPS, Universitat de Barcelona, Barcelona, Spain Centro de Investigaciones Biomédicas en Red de Enfermedades Respiratorias (CIBERES), Barcelona, Spain PubMed articlesGoogle scholar articles
  • Google scholar articles
  1. Correspondence to Dr Maria del Carmen Vennera, Department of Pneumology and Respiratory Allergy, Hospital Clinic, Barcelona 08036, Spain; mvennera{at}hotmail.com
View Full Text

Citation

Vennera MDC, Sabadell C, Picado C on behalf of The Spanish Omalizumab Registry
Duration of the efficacy of omalizumab after treatment discontinuation in ‘real life’ severe asthma

Publication history

  • Received January 18, 2017
  • Revised October 6, 2017
  • Accepted October 9, 2017
  • First published October 27, 2017.
Online issue publication 
July 13, 2018

Article Versions

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.